Cortactin gene amplification and expression in breast cancer: A chromogenic in situ hybridisation and immunohistochemical study

Breast Cancer Research and Treatment

Volumn 124, Issue 3, 2010, Pages 653-666

  Dedes, Konstantin J ^a   Lopez Garcia, Maria Angeles ^a,b   Geyer, Felipe C ^a   Lambros, Maryou B K ^a   Savage, Kay ^a   Vatcheva, Radost ^a   Wilkerson, Paul ^a   Wetterskog, Daniel ^a   Lacroix Triki, Magali ^a,c   Natrajan, Rachael ^a   Reis Filho, Jorge S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

11q13 amplification; Breast cancer; CCND1; Chromogenic in situ hybridisation; CTTN; Immunohistochemistry

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAVEOLIN 1; CAVEOLIN 2; CORTACTIN; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 5; CYTOKERATIN 6; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IIALPHA; EPIDERMAL GROWTH FACTOR RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; KI 67 ANTIGEN; NESTIN; PROTEIN P53; TAMOXIFEN; UNCLASSIFIED DRUG;

AMPLICON; ARTICLE; BREAST CANCER; CANCER INVASION; CHROMOGENIC IN SITU HYBRIDIZATION; CHROMOSOME 11Q; CORTACTIN GENE; CYCLIN D1 GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHROMOGENIC COMPOUNDS; CHROMOSOMES, HUMAN, PAIR 11; CORTACTIN; CYCLIN D1; DIGOXIGENIN; DISEASE-FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN-MEIER ESTIMATE; LONDON; MASTECTOMY; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 78649334369     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0816-0     Document Type: Article

References (62)

1. SA Weed JT Parsons 2001 Cortactin: coupling membrane dynamics to cortical actin assembly Oncogene 20 6418 6434 1:CAS:528:DC%2BD3MXnvVegsLY%3D 10.1038/sj.onc.1204783 11607842 (Pubitemid 32977848)
2. AM Weaver 2008 Cortactin in tumor invasiveness Cancer Lett 265 157 166 1:CAS:528:DC%2BD1cXmtlWhsL8%3D 10.1016/j.canlet.2008.02.066 18406052
3. E Schuuring E Verhoeven WJ Mooi, et al. 1992 Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas Oncogene 7 355 361 1:CAS:528:DyaK38XhvFWrtb8%3D 1532244
4. AG Ammer SA Weed 2008 Cortactin branches out: roles in regulating protrusive actin dynamics Cell Motil Cytoskeleton 65 687 707 1:CAS:528:DC%2BD1cXhtFSlurvM 10.1002/cm.20296 18615630
5. SF Chin Y Wang NP Thorne, et al. 2007 Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers Oncogene 26 1959 1970 1:CAS:528:DC%2BD2sXjtlWgt78%3D 10.1038/sj.onc.1209985 17001317 (Pubitemid 46474632)
6. R Natrajan MB Lambros SM Rodriguez-Pinilla, et al. 2009 Tiling path genomic profiling of grade 3 invasive ductal breast cancers Clin Cancer Res 15 8 2711 2722 1:CAS:528:DC%2BD1MXksV2nsb0%3D 10.1158/1078-0432.CCR-08-1878 19318498
7. A Letessier F Sircoulomb C Ginestier, et al. 2006 Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers BMC Cancer 6 245 10.1186/1471-2407-6-245 17040570 (Pubitemid 44696826)
8. R Hui JR Ball RD Macmillan, et al. 1998 EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival Oncogene 17 1053 1059 1:CAS:528:DyaK1cXmtVSrtrY%3D 10.1038/sj.onc.1202023 9747885
9. JS Reis-Filho K Savage MB Lambros, et al. 2006 Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis Mod Pathol 19 999 1009 1:CAS:528:DC%2BD28Xls1KitLY%3D 10.1038/modpathol.3800621 16648863
10. K Al-Kuraya P Schraml J Torhorst, et al. 2004 Prognostic relevance of gene amplifications and coamplifications in breast cancer Cancer Res 64 8534 8540 1:CAS:528:DC%2BD2cXhtVCjs7zJ 10.1158/0008-5472.CAN-04-1945 15574759 (Pubitemid 39552065)
11. F Courjal C Theillet 1997 Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification Cancer Res 57 4368 4377 1:CAS:528:DyaK2sXmsFCgsrg%3D 9331100
12. T Oyama K Kashiwabara K Yoshimoto, et al. 1998 Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast Cancer Res 58 2876 2880 1:CAS:528:DyaK1cXksFCqtLo%3D 9661905
13. M Cuny A Kramar F Courjal, et al. 2000 Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations Cancer Res 60 1077 1083 1:CAS:528:DC%2BD3cXhs1ShsLc%3D 10706127
14. E Schuuring E Verhoeven H van Tinteren, et al. 1992 Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer Cancer Res 52 5229 5234 1:CAS:528:DyaK38XmtlWhtbY%3D 1394126
15. S Elsheikh AR Green MA Aleskandarany, et al. 2008 CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome Breast Cancer Res Treat 109 325 335 1:CAS:528:DC%2BD1cXlsV2ntr8%3D 10.1007/s10549-007-9659-8 17653856 (Pubitemid 351644857)
16. Roy PG, Pratt N, Purdie CA et al (2009) High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer. Int J Cancer
17. R Hui DH Campbell CS Lee, et al. 1997 EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer Oncogene 15 1617 1623 1:CAS:528:DyaK2sXmslyntLg%3D 10.1038/sj.onc.1201311 9380415
18. K Jirstrom M Stendahl L Ryden, et al. 2005 Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification Cancer Res 65 8009 8016 16140974
19. K Lundgren K Holm B Nordenskjold, et al. 2008 Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer Breast Cancer Res 10 R81 10.1186/bcr2150 18823530
20. CJ Ormandy EA Musgrove R Hui, et al. 2003 Cyclin D1, EMS1 and 11q13 amplification in breast cancer Breast Cancer Res Treat 78 323 335 1:CAS:528:DC%2BD3sXisFKgsbY%3D 10.1023/A:1023033708204 12755491 (Pubitemid 36543212)
21. JP Rodrigo LA Garcia S Ramos, et al. 2000 EMS1 gene amplification correlates with poor prognosis in squamous cell carcinomas of the head and neck Clin Cancer Res 6 3177 3182 1:CAS:528:DC%2BD3cXmsVOmtrk%3D 10955801
22. Bocanegra M, Bergamaschi A, Kim YH et al (2010) Focal amplification and oncogene dependency of GAB2 in breast cancer. Oncogene 29(5):774-779
23. SS Kwek R Roy H Zhou, et al. 2009 Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis Oncogene 28 1892 1903 1:CAS:528:DC%2BD1MXjsl2gu70%3D 10.1038/onc.2009.34 19330026
24. N Chunder S Mandal A Roy, et al. 2004 Analysis of different deleted regions in chromosome 11 and their interrelations in early- and late-onset breast tumors: association with cyclin D1 amplification and survival Diagn Mol Pathol 13 172 182 10.1097/01.pas.0000124337.49401.0b 15322430 (Pubitemid 39121744)
25. M Mottolese G Orlandi I Sperduti, et al. 2007 Bio-pathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage I and II breast cancer: Identification of an adverse prognostic profile Am J Surg Pathol 31 247 254 10.1097/01.pas.0000213345.63228. 8d 17255770 (Pubitemid 46175026)
26. J Kao JR Pollack 2006 RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes Genes Chromosom Cancer 45 761 769 1:CAS:528:DC%2BD28XmvVGrtbc%3D 10.1002/gcc.20339 16708353
27. Natrajan R, Weigelt B, Mackay A et al (2009) An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat. doi: 10.1007/s10549-009-0501-3
28. C Marchio M Iravani R Natrajan, et al. 2009 Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components J Pathol 218 301 315 1:CAS:528: DC%2BD1MXoslOkt70%3D 10.1002/path.2572 19479727
29. C Marchio M Iravani R Natrajan, et al. 2008 Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast J Pathol 215 398 410 1:STN:280:DC%2BD1cvksFKhuw%3D%3D 10.1002/path.2368 18484683
30. C Marchio R Natrajan KK Shiu, et al. 2008 The genomic profile of HER2-amplified breast cancers: the influence of ER status J Pathol 216 399 407 1:STN:280:DC%2BD1cjjsVKhuw%3D%3D 10.1002/path.2423 18810758
31. G Callagy P Pharoah SF Chin, et al. 2005 Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays J Pathol 205 388 396 1:CAS:528:DC%2BD2MXit1Orurs%3D 10.1002/path.1694 15682439 (Pubitemid 40253928)
32. JP Rodrigo D Garcia-Carracedo LA Garcia, et al. 2009 Distinctive clinicopathological associations of amplification of the cortactin gene at 11q13 in head and neck squamous cell carcinomas J Pathol 217 516 523 1:CAS:528:DC%2BD1MXjvFOlsrw%3D 10.1002/path.2462 18991334
33. ML Luo XM Shen Y Zhang, et al. 2006 Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance Cancer Res 66 11690 11699 1:CAS:528:DC%2BD28XhtlagurfF 10.1158/0008-5472.CAN-06-1484 17178864 (Pubitemid 46094181)
34. M Chuma M Sakamoto J Yasuda, et al. 2004 Overexpression of cortactin is involved in motility and metastasis of hepatocellular carcinoma J Hepatol 41 629 636 1:CAS:528:DC%2BD2cXotF2isLY%3D 10.1016/j.jhep.2004.06.018 15464244 (Pubitemid 39297799)
35. ET Bowden M Barth D Thomas, et al. 1999 An invasion-related complex of cortactin, paxillin and PKCmu associates with invadopodia at sites of extracellular matrix degradation Oncogene 18 4440 4449 1:CAS:528: DyaK1MXlsVOksLw%3D 10.1038/sj.onc.1202827 10442635 (Pubitemid 29396652)
36. Y Li M Tondravi J Liu, et al. 2001 Cortactin potentiates bone metastasis of breast cancer cells Cancer Res 61 6906 6911 1:CAS:528:DC%2BD3MXntFaitrs%3D 11559568
37. A Hill S McFarlane K Mulligan, et al. 2006 Cortactin underpins CD44-promoted invasion and adhesion of breast cancer cells to bone marrow endothelial cells Oncogene 25 6079 6091 1:CAS:528:DC%2BD28XhtVGgsr7M 10.1038/sj.onc.1209628 16652145 (Pubitemid 44562406)
38. BL Rothschild AH Shim AG Ammer, et al. 2006 Cortactin overexpression regulates actin-related protein 2/3 complex activity, motility, and invasion in carcinomas with chromosome 11q13 amplification Cancer Res 66 8017 8025 1:CAS:528:DC%2BD28XotFWqt7o%3D 10.1158/0008-5472.CAN-05-4490 16912177 (Pubitemid 44299166)
39. ES Clark B Brown AS Whigham, et al. 2009 Aggressiveness of HNSCC tumors depends on expression levels of cortactin, a gene in the 11q13 amplicon Oncogene 28 431 444 1:CAS:528:DC%2BD1MXosVWlsA%3D%3D 10.1038/onc.2008.389 18931703
40. CW Elston IO Ellis 1991 Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 403 410 1:STN:280: DyaK38%2FpvVSltw%3D%3D 10.1111/j.1365-2559.1991.tb00229.x 1757079
41. SE Singletary JL Connolly 2006 Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual CA Cancer J Clin 56 37 47 10.3322/canjclin.56.1.37 16449185 quiz 50-51
42. MB Lambros PT Simpson C Jones, et al. 2006 Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization Lab Invest 86 398 408 1:CAS:528:DC%2BD28Xis1Grsbw%3D 10.1038/labinvest.3700390 16446704
43. DS Tan MB Lambros S Rayter, et al. 2009 PPM1D is a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269 2280 1:CAS:528:DC%2BD1MXjvVWltLg%3D 10.1158/1078-0432.CCR-08-2403 19293255
44. A Mackay N Tamber K Fenwick, et al. 2009 A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines Breast Cancer Res Treat 118 481 498 1:CAS:528:DC%2BD1MXhtlyls7%2FK 10.1007/s10549-008- 0296-7 19169812
45. S Detre G Saclani Jotti M Dowsett 1995 A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas J Clin Pathol 48 876 878 1:STN:280:DyaK28%2Fps1arsQ%3D%3D 10.1136/jcp.48.9.876 7490328
46. DS Tan C Marchio RL Jones, et al. 2008 Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients Breast Cancer Res Treat 111 27 44 1:CAS:528:DC%2BD1cXos1Wnsbs%3D 10.1007/s10549-007-9756-8 17922188 (Pubitemid 352009225)
47. B Mahler-Araujo K Savage S Parry, et al. 2008 Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype J Clin Pathol 61 615 620 1:STN:280: DC%2BD1c3nsFGhsA%3D%3D 10.1136/jcp.2007.053991 18156431 (Pubitemid 351678214)
48. S Parry K Savage C Marchio, et al. 2008 Nestin is expressed in basal-like and triple negative breast cancers J Clin Pathol 61 1045 1050 1:STN:280:DC%2BD1crkvFGqtw%3D%3D 10.1136/jcp.2008.058750 18641405
49. MA Thorat C Marchio A Morimiya, et al. 2008 Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis J Clin Pathol 61 327 332 1:STN:280:DC%2BD1c7ksVamtQ%3D%3D 10.1136/jcp.2007.052431 18037662 (Pubitemid 351354239)
50. P Klingbeil R Natrajan G Everitt, et al. 2010 CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification Breast Cancer Res Treat 120 95 109 1:CAS:528:DC%2BC3cXntlarsQ%3D%3D 10.1007/s10549-009-0380-7 19350388
51. K Savage S Leung SK Todd, et al. 2008 Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis Breast Cancer Res Treat 110 245 256 1:CAS:528:DC%2BD1cXmslygsr4%3D 10.1007/s10549-007-9718-1 17912630 (Pubitemid 351793874)
52. TO Nielsen FD Hsu K Jensen, et al. 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 5367 5374 1:CAS:528:DC%2BD2cXmvFSlt7k%3D 10.1158/1078-0432.CCR-04- 0220 15328174 (Pubitemid 39100473)
53. F Courjal M Cuny J Simony-Lafontaine, et al. 1997 Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups Cancer Res 57 4360 4367 1:CAS:528:DyaK2sXmsFCgsrs%3D 9331099
54. SF Chin AE Teschendorff JC Marioni, et al. 2007 High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer Genome Biol 8 R215 10.1186/gb-2007-8-10-r215 17925008 (Pubitemid 351917462)
55. P Hofman C Butori K Havet, et al. 2008 Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: comparison with epidermal growth factor receptor status Br J Cancer 98 956 964 1:CAS:528:DC%2BD1cXivVOgtLg%3D 10.1038/sj.bjc.6604245 18268492 (Pubitemid 351341605)
56. DK Lynch SC Winata RJ Lyons, et al. 2003 A Cortactin-CD2-associated protein (CD2AP) complex provides a novel link between epidermal growth factor receptor endocytosis and the actin cytoskeleton J Biol Chem 278 21805 21813 1:CAS:528:DC%2BD3sXksVemtr0%3D 10.1074/jbc.M211407200 12672817 (Pubitemid 36792585)
57. P Timpson DK Lynch D Schramek, et al. 2005 Cortactin overexpression inhibits ligand-induced down-regulation of the epidermal growth factor receptor Cancer Res 65 3273 3280 1:CAS:528:DC%2BD2MXjt1yku7o%3D 15833860
58. G Ren FM Helwani S Verma, et al. 2009 Cortactin is a functional target of E-cadherin-activated Src family kinases in MCF7 epithelial monolayers J Biol Chem 284 18913 18922 1:CAS:528:DC%2BD1MXotVKntr8%3D 10.1074/jbc.M109.000307 19457864
59. RM Neve K Chin J Fridlyand, et al. 2006 A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes Cancer Cell 10 515 527 1:CAS:528:DC%2BD28XhtlCnsrbE 10.1016/j.ccr.2006.10.008 17157791 (Pubitemid 44854747)
60. F Huang K Reeves X Han, et al. 2007 Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection Cancer Res 67 2226 2238 1:CAS:528:DC%2BD2sXitlSjs7g%3D 10.1158/0008-5472.CAN-06-3633 17332353 (Pubitemid 46424242)
61. RS Finn J Dering C Ginther, et al. 2007 Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro Breast Cancer Res Treat 105 319 326 1:CAS:528:DC%2BD2sXhtFSlsr3N 10.1007/s10549-006-9463-x 17268817 (Pubitemid 47596452)
62. M Tan P Li M Sun, et al. 2006 Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors Oncogene 25 3286 3295 1:CAS:528:DC%2BD28XltFWku7g%3D 10.1038/sj.onc.1209361 16407820 (Pubitemid 43846313)